PMID- 33587488
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1537-162X (Electronic)
IS  - 0362-5664 (Linking)
VI  - 44
IP  - 3
DP  - 2021 May-Jun 01
TI  - Rituximab Was Effective for Treatment of Anti-N-Methyl-d-Aspartate Receptor 
      Encephalitis in Early Adolescence in Initially Suspected Dissociative Disorder.
PG  - 99-100
LID - 10.1097/WNF.0000000000000443 [doi]
AB  - OBJECTIVES: Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is an 
      increasingly recognized etiology of psychiatric symptoms. Because patients with 
      anti-NMDAR encephalitis frequently show aggression, mania, hallucination, 
      depression, or delusion, they are initially diagnosed with schizophrenia or mood 
      disorders. There is only 1 case report of an initially diagnosed dissociative 
      disorder. METHODS: We obtained consent for the presentation and have not 
      identified individuals for ethical reasons. RESULTS: We first report an 
      adolescent female patient with anti-NMDAR encephalitis who was initially 
      suspected of having dissociative disorder but was responsive to immunotherapies 
      including rituximab. In this case, her symptoms and electroencephalogram findings 
      were proportional to the antibody titer in the cerebrospinal fluid. CONCLUSIONS: 
      It is important to consider the possibility of autoimmune encephalitis and 
      immunotherapy including rituximab in cases of not only acute psychosis but also 
      dissociation.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Shibata, Takashi
AU  - Shibata T
AD  - Departments of Child Neurology.
FAU - Kawai, Hiroki
AU  - Kawai H
AD  - Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and 
      Pharmaceutical Sciences, Okayama.
FAU - Sakamoto, Shinji
AU  - Sakamoto S
AD  - Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and 
      Pharmaceutical Sciences, Okayama.
FAU - Tsutsui, Ko
AU  - Tsutsui K
AD  - Department of Neuropsychiatry, Akita University Graduate School of Medicine, 
      Akita.
FAU - Kanbayashi, Takashi
AU  - Kanbayashi T
AD  - International Institute for Integrative Sleep Medicine (WPI-IIIS), University of 
      Tsukuba, Tsukuba.
FAU - Tanaka, Keiko
AU  - Tanaka K
AD  - Brain Research Institute, Niigata University Graduate School of Medicine, 
      Niigata, Japan.
FAU - Takaki, Manabu
AU  - Takaki M
AD  - Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and 
      Pharmaceutical Sciences, Okayama.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Clin Neuropharmacol
JT  - Clinical neuropharmacology
JID - 7607910
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Adolescent
MH  - *Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis/drug therapy
MH  - Dissociative Disorders
MH  - Female
MH  - Humans
MH  - *Psychotic Disorders
MH  - Receptors, N-Methyl-D-Aspartate
MH  - Rituximab/therapeutic use
COIS- Conflicts of Interest and Source of Funding: This research was supported in part 
      by JSPS KAKENHI grant numbers 16K10188 and 19K08019 (to M.T.), Kobayashi Magobe 
      Memorial Medical Foundation (to M.T.), and the Okayama Medical Foundation (to 
      M.T.). The authors have no conflicts of interest to declare.
EDAT- 2021/02/16 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/02/15 14:03
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2021/02/15 14:03 [entrez]
AID - 00002826-900000000-99471 [pii]
AID - 10.1097/WNF.0000000000000443 [doi]
PST - ppublish
SO  - Clin Neuropharmacol. 2021 May-Jun 01;44(3):99-100. doi: 
      10.1097/WNF.0000000000000443.